SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study

SARS-CoV-2-specific immune responses in elderly and immunosuppressed participants and patients with hematologic disease or checkpoint inhibition in solid tumors: study protocol of the prospective, observational CoCo immune study

Background: Immunocompromised people (ICP) and elderly individuals (older than 80 years) are at increased risk for severe coronavirus infections. To protect against serious infection with SARS-CoV-2, ICP are taking precautions that may include a reduction of social contacts and participation in acti...

Full description

Bibliographic Details
Main Authors: Behrens, G.M.N (Author), Cossmann, A. (Author), Dopfer-Jablonka, A. (Author), Falk, C.S (Author), Hasenkamp, J. (Author), Heesen, G. (Author), Heinemann, S. (Author), Hummers, E. (Author), Kallusky, J. (Author), Klawonn, F. (Author), Mikuteit, M. (Author), Müller, F. (Author), Niewolik, J. (Author), Overbeck, T.R (Author), Roder, S. (Author), Schröder, D. (Author), Stankov, M.V (Author), Steffens, S. (Author), Vahldiek, K. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
Checkpoint inhibition
Coronavirus
COVID-19
Elderly
Hematology
Humoral and cellular immunity
Immunocompromised people
Immunogenicity
Pandemic
SARS-CoV-2
Serological testing
Social participation
Solid tumor
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items